PT3209295T - Métodos de tratamento das condições oculares - Google Patents

Métodos de tratamento das condições oculares

Info

Publication number
PT3209295T
PT3209295T PT158523407T PT15852340T PT3209295T PT 3209295 T PT3209295 T PT 3209295T PT 158523407 T PT158523407 T PT 158523407T PT 15852340 T PT15852340 T PT 15852340T PT 3209295 T PT3209295 T PT 3209295T
Authority
PT
Portugal
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
PT158523407T
Other languages
English (en)
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3209295(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of PT3209295T publication Critical patent/PT3209295T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
PT158523407T 2014-10-20 2015-10-19 Métodos de tratamento das condições oculares PT3209295T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US201562100844P 2015-01-07 2015-01-07

Publications (1)

Publication Number Publication Date
PT3209295T true PT3209295T (pt) 2021-02-05

Family

ID=55748136

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158523407T PT3209295T (pt) 2014-10-20 2015-10-19 Métodos de tratamento das condições oculares

Country Status (19)

Country Link
US (10) US9532944B2 (pt)
EP (2) EP3209295B2 (pt)
JP (3) JP6873906B2 (pt)
KR (2) KR102511955B1 (pt)
CN (3) CN111956803A (pt)
AU (2) AU2015336216B2 (pt)
BR (2) BR112017008097B1 (pt)
CA (1) CA2965129C (pt)
DK (1) DK3209295T4 (pt)
EA (1) EA035335B1 (pt)
ES (1) ES2848977T3 (pt)
IL (2) IL293188A (pt)
MX (2) MX2017005064A (pt)
MY (1) MY186870A (pt)
PH (1) PH12017500602A1 (pt)
PT (1) PT3209295T (pt)
SG (2) SG11201703135XA (pt)
WO (1) WO2016064759A1 (pt)
ZA (1) ZA201703467B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008097B1 (pt) 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
CN114432313A (zh) * 2016-04-07 2022-05-06 奥伊斯特普安生物制药公司 治疗眼部病状的方法
WO2020014232A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
BR0214559A (pt) 2001-11-29 2007-03-13 Pfizer Prod Inc sais de ácido succìnico do 5,8,14-triazatetraciclo [10.3.1.0<2,11>.0<4,9>]-hexadeca-2(11),3,5,7,9-penteno e suas composições farmacêuticas
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
JP2008516942A (ja) * 2004-10-15 2008-05-22 ファイザー・プロダクツ・インク バレニクリンの鼻腔内、バッカル、舌下および肺送達のための組成物および方法
WO2006050836A2 (en) * 2004-11-09 2006-05-18 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
EP1885332A2 (en) * 2005-03-22 2008-02-13 NicoNovum AB Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2008093227A1 (en) * 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
RU2010140613A (ru) 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
ES2820857T3 (es) 2008-12-01 2021-04-22 Oyster Point Pharma Inc Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
KR20140027939A (ko) * 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제
BR112014007485B1 (pt) * 2011-10-20 2022-05-31 Novartis Ag Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador
EP3029463A1 (en) * 2011-11-30 2016-06-08 DiagnosTear Ltd Dry eye diagnostic
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
US10155108B2 (en) 2013-04-19 2018-12-18 Oculeve, Inc. Nasal stimulation devices and methods
BR112017008097B1 (pt) * 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
CN114432313A (zh) 2016-04-07 2022-05-06 奥伊斯特普安生物制药公司 治疗眼部病状的方法
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法

Also Published As

Publication number Publication date
JP6873906B2 (ja) 2021-05-19
EP3848028A1 (en) 2021-07-14
JP2017531044A (ja) 2017-10-19
CA2965129C (en) 2024-03-12
MY186870A (en) 2021-08-26
US20230226053A1 (en) 2023-07-20
IL293188A (en) 2022-07-01
CN107106542A (zh) 2017-08-29
MX2017005064A (es) 2018-02-23
US11911380B2 (en) 2024-02-27
SG10202011669PA (en) 2020-12-30
CN111956650A (zh) 2020-11-20
CN107106542B (zh) 2020-05-08
CA2965129A1 (en) 2016-04-28
SG11201703135XA (en) 2017-05-30
EP3209295B1 (en) 2020-12-09
CN111956803A (zh) 2020-11-20
US20160106744A1 (en) 2016-04-21
BR112017008097A2 (pt) 2018-02-20
ES2848977T3 (es) 2021-08-13
PH12017500602A1 (en) 2017-09-04
US20160106665A1 (en) 2016-04-21
AU2015336216A1 (en) 2017-06-08
JP2021038250A (ja) 2021-03-11
US11903942B2 (en) 2024-02-20
US20230226054A1 (en) 2023-07-20
KR102601505B1 (ko) 2023-11-14
EP3209295A1 (en) 2017-08-30
BR122022025737B1 (pt) 2023-12-26
EP3209295B2 (en) 2023-12-06
US10456396B2 (en) 2019-10-29
US20230226052A1 (en) 2023-07-20
EA201790893A1 (ru) 2018-01-31
US9504645B2 (en) 2016-11-29
US9532944B2 (en) 2017-01-03
WO2016064759A1 (en) 2016-04-28
EP3848028B1 (en) 2024-05-29
US20170239244A1 (en) 2017-08-24
EA035335B1 (ru) 2020-05-28
ZA201703467B (en) 2023-12-20
AU2020213351A1 (en) 2020-08-27
BR112017008097B1 (pt) 2023-03-28
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
US9597284B2 (en) 2017-03-21
US11903943B2 (en) 2024-02-20
JP2023024574A (ja) 2023-02-16
US9504644B2 (en) 2016-11-29
IL251769B (en) 2022-06-01
IL251769A0 (en) 2017-06-29
KR20230042144A (ko) 2023-03-27
US11224598B2 (en) 2022-01-18
JP7257371B2 (ja) 2023-04-13
DK3209295T3 (da) 2021-03-01
KR102511955B1 (ko) 2023-03-22
EP3209295A4 (en) 2018-05-23
US20160106745A1 (en) 2016-04-21
KR20170086040A (ko) 2017-07-25
AU2015336216B2 (en) 2020-05-21
AU2020213351B2 (en) 2023-04-06
MX2022005888A (es) 2022-06-14
US20200246336A1 (en) 2020-08-06
US11903941B2 (en) 2024-02-20
DK3209295T4 (da) 2024-02-26

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
GB201701673D0 (en) Methods of well treatment
HK1246179A1 (zh) 治療視網膜疾病的方法
IL257252A (en) Methods for treating fgf21-related disorders
IL246791A0 (en) Compositions and methods for treating eye diseases
HK1248552A1 (zh) 使用川地匹坦的治療方法
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL290069A (en) Methods for treating eye conditions
GB201410116D0 (en) Method of treatment
IL251769A0 (en) Methods for treating eye conditions
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
HK1244692A1 (zh) 治療纖維化的方法
HK1243937A1 (zh) 治療疾病的方法
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
GB201511017D0 (en) Method of treatment
AU2014905194A0 (en) Method of Treatment
AU2014904907A0 (en) Method of Treatment
AU2014904371A0 (en) Method of treatment